Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (HK:4332)
HKEX:4332
Amgen (4332) Stock Price & Analysis
0 Followers
4332 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$600.15 - HK$666.00
Previous CloseHK$666
Volume0.00
Average Volume (3M)N/A
Market Cap
HK$1.39T
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)33.8
Beta0.00
Next Earnings
Aug 06, 2024EPS Estimate
HK$39Last Dividend Ex-Date
May 16, 2024Dividend Yield2.64%
Share Statistics
EPS (TTM)54.74
Shares Outstanding536,434,692
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.59
R-Squared0.65
Alpha0.36
Financial Highlights & Ratios
Price to Book (P/B)-3.68
Price to Sales (P/S)35.20
Price to Cash Flow (P/CF)60.00
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2,524.31Price Target Upside279.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Amgen News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And PipelineThe Ph3 trial of Uplizna in Immunoglobulin G4-related disease (IgG4-RD) showed an 87% reduction in risk of IgG4-RD flares versus placebo and met all key secondary endpoints.
Sales PerformanceIQVIA Script (TRx) data suggests AMGN 2Q24 volume is up 28% year-over-year and may lead to top-line sales of approximately $8.4 billion, edging ahead of the Street's estimate of around $8.3 billion.
Technology And InnovationAMGN has been investing in technology and artificial intelligence for over 5 years and is already seeing returns.
Bears Say
Financial PerformanceLowering denosumab franchise worldwide sales by 20% due to expected biosimilar competition following the recent settlement with Sandoz.
Operational IssuesAmgen confirmed cybersecurity issues in February and March significantly impacted Otezla prescriptions.
Product PerformanceProduct sales came in about $100MM light driven by weak Enbrel, Neulasta, Nplate, Otezla, Tepezza and offset by Repatha.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
22.91% Mutual Funds
28.30% Other Institutional Investors
47.71% Public Companies and
Individual Investors
4332 FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was HK$600.15 and its highest was HK$666.00 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on May 02, 2024. The company reported HK$30.931 earnings per share for the quarter, beating the consensus estimate of HK$30.298 by HK$0.633.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of HK$17.57 which represents an annual dividend yield of 2.64%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is HK$39.
How many shares outstanding does Amgen have?
Amgen has 536,434,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of HK$30.931 in its last earnings report, beating expectations of HK$30.298. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$2,524.31 (279.03% Upside)
HK$2,524.31 (279.03% Upside)
Blogger Sentiment
Bullish
HK:4332 Sentiment 89%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.22%
12-Months-Change
Fundamentals
Return on Equity
72.57%
Trailing 12-Months
Asset Growth
4.80%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
4332 Company Deck
---
4332 Earnings Call
Q1 2024
0:00 / 0:00
---
4332 Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
4332 Stock 12 Month Forecast
Average Price Target
HK$2,524.31
▲(279.03% Upside)
Technical Analysis
Best Analysts Covering 4332
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+17.99%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +17.99% per trade.
---